NCT01958164View on ClinicalTrials.gov

Efficacy and Safety of Actilyse 2 mg/ 2 ml in Comparison to Saline Solution in Patients With Central Venous Access Device Occlusion

PHASE3CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

April 30, 2014

Study Completion Date

April 30, 2014

Conditions
Catheter ObstructionVascular Access Devices
Interventions
DRUG

Actilyse

Actilyse 2mg/2ml will be given if the CVAD has not been restored at time 120min.

DRUG

Saline solution

Instil Saline solution 2 ml into the disfunctional CVAD once at time O only for patients enrolled in Group II

DRUG

Actilyse

Instil Actilyse 2 mg/ 2 ml into the dysfunctional CVAD at time O.

DRUG

Actilyse

Second dose of Actilyse 2mg/2ml will be given if CVAD has not been restored at time 120min.

Trial Locations (5)

Unknown

135.323.1 Boehringer Ingelheim Investigational Site, Akhangelsk

135.323.2 Boehringer Ingelheim Investigational Site, Krasnodar

135.323.3 Boehringer Ingelheim Investigational Site, Krasnoyarsk

135.323.7 Boehringer Ingelheim Investigational Site, Saint Petersburg

135.323.5 Boehringer Ingelheim Investigational Site, Samara

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT01958164 - Efficacy and Safety of Actilyse 2 mg/ 2 ml in Comparison to Saline Solution in Patients With Central Venous Access Device Occlusion | Biotech Hunter | Biotech Hunter